$68.98
+3.63 (+5.55%)
Open$65.11
Previous Close$65.35
Day High$69.00
Day Low$64.28
52W High$240.00
52W Low$4.28
Volume—
Avg Volume37.8K
Market Cap94.82M
P/E Ratio—
EPS$-53.34
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-35.1% upside
Current
$68.98
$68.98
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.25M | 53.02M | 47.19M |
| Net Income | -110,695,812 | 1.91M | 1.39M |
| Profit Margin | -1,079.9% | 3.6% | 2.9% |
| EBITDA | -109,958,977 | 2.67M | 2.51M |
| Free Cash Flow | — | 1.24M | 802.3K |
| Rev Growth | — | +15.8% | -2.9% |
| Debt/Equity | 0.06 | 0.46 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |